Novo Nordisk A/S Common Stock (NVO)
81.05
+2.32 (2.95%)
NYSE · Last Trade: Jun 12th, 5:57 PM EDT
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.
Via Stocktwits · June 12, 2025
Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.
Via Benzinga · June 12, 2025
The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.
Via The Motley Fool · June 12, 2025
Via The Motley Fool · June 12, 2025
Via The Motley Fool · June 12, 2025
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Via Benzinga · June 11, 2025
Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent.
Via Investor's Business Daily · June 11, 2025
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.
Via Stocktwits · June 11, 2025
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Via Benzinga · June 11, 2025
Novo Nordisk stock has multiple catalysts that could soon reverse is slide.
Via The Motley Fool · June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via Investor's Business Daily · June 9, 2025
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via Benzinga · June 9, 2025
Via The Motley Fool · June 8, 2025
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via MarketBeat · June 7, 2025
Via The Motley Fool · June 7, 2025
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.
Via Benzinga · June 6, 2025

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.
Via Benzinga · June 3, 2025